Endo Pharmaceutical Holdings, Inc. has a market cap of $3.05 billion; its shares were traded at around $26.39 with a P/E ratio of 5.4 and P/S ratio of 1.1. Endo Pharmaceutical Holdings, Inc. had an annual average earning growth of 31.7% over the past 10 years. GuruFocus rated Endo Pharmaceutical Holdings, Inc. the business predictability rank of 4-star.
This is the annual revenues and earnings per share of ENDP over the last 10 years. For detailed 10-year financial data and charts, go to 10-Year Financials of ENDP.
CEO Recent Trades:
- President & CEO David Holveck bought 7,425 shares of ENDP stock on 11/12/2012 at the average price of 26.84. David Holveck owns at least 31,497 shares after this. The price of the stock has decreased by 1.68% since.
- President & CEO David Holveck bought 8,550 shares of ENDP stock on 06/12/2012 at the average price of 29.23. David Holveck owns at least 24,072 shares after this. The price of the stock has decreased by 9.72% since.
CFO Recent Trades:
- EVP, CFO Alan G Levin bought 3,200 shares of ENDP stock on 06/15/2012 at the average price of 29.68. Alan G Levin owns at least 3,200 shares after this. The price of the stock has decreased by 11.08% since.
This is the insider trade history vs. stock price of ENDP. For the complete insider trading history of ENDP, click here.
Directors and Officers Recent Trades:
- Vice President, Controller Daniel Rudio sold 1,957 shares of ENDP stock on 08/10/2012 at the average price of 32.23. Daniel Rudio owns at least 292 shares after this. The price of the stock has decreased by 18.12% since.
For the complete insider trading history of ENDP, click here.







RSS